Download PDF
Semin Neurol 2021; 41(01): 028-038
DOI: 10.1055/s-0040-1722722
Review Article

Tenecteplase for Acute Ischemic Stroke Treatment

Alison E. Baird
1   SUNY Downstate Medical Center, Brooklyn, New York
,
Richard Jackson
1   SUNY Downstate Medical Center, Brooklyn, New York
,
Weijun Jin
1   SUNY Downstate Medical Center, Brooklyn, New York
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis with fewer hemorrhagic complications. Also, easier bolus-only administration makes TNK a very practical rt-PA alternative. In several clinical trials, TNK has shown similar efficacy and safety to rt-PA, and the potential to be at least noninferior to rt-PA in some settings. TNK may be superior to rt-PA for reperfusing large vessel occlusions in patients with salvageable penumbra, although this has not yet translated to improved clinical outcomes. Further phase 3 studies are in progress comparing rt-PA with TNK for acute ischemic stroke during the first 4.5 hours. Studies are also in progress to evaluate the use of TNK for extended applications, such as wake-up stroke.

Keywords

stroke - treatment - tenecteplase - alteplase - recombinant tissue plasminogen activator - intravenous thrombolysis


Publication History

Article published online:
20 January 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
    CrossrefPubMedGoogle Scholar
  • 2 Hacke W, Kaste M, Bluhmki E. et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 (13) 1317-1329
    CrossrefPubMedGoogle Scholar
  • 3 Del Zoppo GJ, Saver JL, Jauch EC, Adams Jr HP. American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40 (08) 2945-2948 Erratum in: Stroke 2010;41:e562
    CrossrefPubMedGoogle Scholar
  • 4 Thomalla G, Simonsen CZ, Boutitie F. et al; WAKE-UP Investigators. WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018; 379 (07) 611-622
    CrossrefPubMedGoogle Scholar
  • 5 Ma H, Campbell BCV, Parsons MW. et al; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019; 380 (19) 1795-1803
    CrossrefPubMedGoogle Scholar
  • 6 Campbell BCV, Ma H, Ringleb PA. et al; EXTEND, ECASS-4, and EPITHET Investigators. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet 2019; 394 (10193): 139-147
    CrossrefPubMedGoogle Scholar
  • 7 Saver JL, Goyal M, Bonafe A. et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015; 372 (24) 2285-2295
    CrossrefPubMedGoogle Scholar
  • 8 Berkhemer OA, Fransen PS, Beumer D. et al. MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20 Erratum in. N Engl J Med 2015; 372: 394
    CrossrefPubMedGoogle Scholar
  • 9 Goyal M, Demchuk AM, Menon BK. et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015; 372 (11) 1019-1030
    CrossrefPubMedGoogle Scholar
  • 10 Campbell BC, Mitchell PJ, Kleinig TJ. et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015; 372 (11) 1009-1018
    CrossrefPubMedGoogle Scholar
  • 11 Jovin TG, Chamorro A, Cobo E. et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015; 372 (24) 2296-2306
    CrossrefPubMedGoogle Scholar
  • 12 Bracard S, Ducrocq X, Mas JL. et al; THRACE investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 2016; 15 (11) 1138-1147 erratum in: Lancet Neurol 2016;15:1203
    CrossrefPubMedGoogle Scholar
  • 13 Mocco J, Zaidat OO, von Kummer R. et al; THERAPY Trial Investigators*. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke 2016; 47 (09) 2331-2338
    CrossrefPubMedGoogle Scholar
  • 14 Heiferman DM, Li DD, Pecoraro NC, Smolenski AM, Tsimpas A, Ashley Jr WW. Intra-arterial alteplase thrombolysis during mechanical thrombectomy for acute ischemic stroke. J Stroke Cerebrovasc Dis 2017; 26 (12) 3004-3008
    CrossrefPubMedGoogle Scholar
  • 15 Nogueira RG, Jadhav AP, Haussen DC. et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378 (01) 11-21
    CrossrefPubMedGoogle Scholar
  • 16 Albers GW, Marks MP, Kemp S. et al; DEFUSE 3 Investigators. DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018; 378 (08) 708-718
    CrossrefPubMedGoogle Scholar
  • 17 Campbell BCV, Mitchell PJ, Churilov L. et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018; 378 (17) 1573-1582
    CrossrefPubMedGoogle Scholar
  • 18 Wei D, Oxley TJ, Nistal DA. et al. Mobile interventional stroke teams lead to faster treatment times for thrombectomy in large vessel occlusion. Stroke 2017; 48 (12) 3295-3300
    CrossrefPubMedGoogle Scholar
  • 19 Menon BK, Al-Ajlan FS, Najm M. et al; INTERRSeCT Study Investigators. Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke. JAMA 2018; 320 (10) 1017-1026
    CrossrefPubMedGoogle Scholar
  • 20 Bhatia R, Hill MD, Shobha N. et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010; 41 (10) 2254-2258
    CrossrefPubMedGoogle Scholar
  • 21 Emberson J, Lees KR, Lyden P. et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384 (9958): 1929-1935
    CrossrefPubMedGoogle Scholar
  • 22 Yaghi S, Willey JZ, Cucchiara B. et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for health care professionals from the American Heart Association/American Stroke Association. Stroke 2017; 48 (12) e343-e361
    CrossrefPubMedGoogle Scholar
  • 23 Seet RC, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis 2012; 34 (02) 106-114
    CrossrefPubMedGoogle Scholar
  • 24 Cornu C, Boutitie F, Candelise L. et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31 (07) 1555-1560
    CrossrefPubMedGoogle Scholar
  • 25 Hacke W, Furlan AJ, Al-Rawi Y. et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8 (02) 141-150
    CrossrefPubMedGoogle Scholar
  • 26 Albers GW, von Kummer R, Truelsen T. et al; DIAS-3 Investigators. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 2015; 14 (06) 575-584
    CrossrefPubMedGoogle Scholar
  • 27 Chester KW, Corrigan M, Schoeffler JM. et al. Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase. Expert Opin Drug Saf 2019; 18 (02) 87-96
    CrossrefPubMedGoogle Scholar
  • 28 Keyt BA, Paoni NF, Refino CJ. et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91 (09) 3670-3674
    CrossrefPubMedGoogle Scholar
  • 29 Nelson A, Kelly G, Byyny R, Dionne C, Preslaski C, Kaucher K. Tenecteplase utility in acute ischemic stroke patients: a clinical review of current evidence. Am J Emerg Med 2019; 37 (02) 344-348
    CrossrefPubMedGoogle Scholar
  • 30 Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002; 41 (15) 1229-1245
    CrossrefPubMedGoogle Scholar
  • 31 Van De Werf F, Adgey J, Ardissino D. et al; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354 (9180): 716-722
    CrossrefPubMedGoogle Scholar
  • 32 Cannon CP, Gibson CM, McCabe CH. et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998; 98 (25) 2805-2814
    CrossrefPubMedGoogle Scholar
  • 33 Coutts SB, Berge E, Campbell BCV, Muir KW, Parsons MW. Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials. Int J Stroke 2018; 13 (09) 885-892
    CrossrefPubMedGoogle Scholar
  • 34 Thomas GR, Thibodeaux H, Errett CJ. et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994; 25 (10) 2072-2078 , discussion 2078–2079
    CrossrefPubMedGoogle Scholar
  • 35 Benedict CR, Refino CJ, Keyt BA. et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92 (10) 3032-3040
    CrossrefPubMedGoogle Scholar
  • 36 Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001; 32 (03) 748-752
    CrossrefPubMedGoogle Scholar
  • 37 Logallo N, Novotny V, Assmus J. et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 2017; 16 (10) 781-788
    CrossrefPubMedGoogle Scholar
  • 38 Haley Jr EC, Lyden PD, Johnston KC, Hemmen TM. TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005; 36 (03) 607-612
    CrossrefPubMedGoogle Scholar
  • 39 Haley Jr EC, Thompson JL, Grotta JC. et al; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010; 41 (04) 707-711
    CrossrefPubMedGoogle Scholar
  • 40 Behrouz R. Intravenous tenecteplase in acute ischemic stroke: an updated review. J Neurol 2014; 261 (06) 1069-1072
    CrossrefPubMedGoogle Scholar
  • 41 Parsons MW, Miteff F, Bateman GA. et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009; 72 (10) 915-921
    CrossrefPubMedGoogle Scholar
  • 42 Parsons M, Spratt N, Bivard A. et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366 (12) 1099-1107
    CrossrefPubMedGoogle Scholar
  • 43 Huang X, Cheripelli BK, Lloyd SM. et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 2015; 14 (04) 368-376
    CrossrefPubMedGoogle Scholar
  • 44 Schwamm LH. Breaking up is hard to do: tenecteplase in acute stroke. Lancet Neurol 2015; 14 (04) 343-345
    CrossrefPubMedGoogle Scholar
  • 45 Bivard A, Huang X, Levi CR. et al. Tenecteplase in ischemic stroke offers improved recanalization: analysis of 2 trials. Neurology 2017; 89 (01) 62-67
    CrossrefPubMedGoogle Scholar
  • 46 Bivard A, Huang X, McElduff P. et al. Impact of computed tomography perfusion imaging on the response to tenecteplase in ischemic stroke: analysis of 2 randomized controlled trials. Circulation 2017; 135 (05) 440-448
    CrossrefPubMedGoogle Scholar
  • 47 Smadja D, Chausson N, Joux J. et al. A new therapeutic strategy for acute ischemic stroke: sequential combined intravenous tPA-tenecteplase for proximal middle cerebral artery occlusion based on first results in 13 consecutive patients. Stroke 2011; 42 (06) 1644-1647
    CrossrefPubMedGoogle Scholar
  • 48 Molina CA. Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke 2011; 42 (1, Suppl): S16-S19
    CrossrefPubMedGoogle Scholar
  • 49 Georgiadis AL, Memon MZ, Shah QA. et al. Intra-arterial tenecteplase for treatment of acute ischemic stroke: feasibility and comparative outcomes. J Neuroimaging 2012; 22 (03) 249-254
    CrossrefPubMedGoogle Scholar
  • 50 Coutts SB, Dubuc V, Mandzia J. et al; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke 2015; 46 (03) 769-774
    CrossrefPubMedGoogle Scholar
  • 51 Kate M, Wannamaker R, Kamble H. et al. Penumbral imaging-based thrombolysis with tenecteplase is feasible up to 24 hours after symptom onset. J Stroke 2018; 20 (03) 415
    CrossrefPubMedGoogle Scholar
  • 52 Ramakrishnan TCR, Kumaravelu S, Narayan SK. et al; Tenecteplase in Stroke Investigators. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label, multicenter trials. Am J Cardiovasc Drugs 2018; 18 (05) 387-395
    CrossrefPubMedGoogle Scholar
  • 53 Owais M, Panwar A, Valupadas C, Veeramalla M. Acute ischemic stroke thrombolysis with tenecteplase: an institutional experience from South India. Ann Afr Med 2018; 17 (02) 90-93
    CrossrefPubMedGoogle Scholar
  • 54 Seners P, Caroff J, Chausson N. et al; PREDICT-RECANAL collaborators. Recanalization before thrombectomy in tenecteplase vs. alteplase-treated drip-and-ship patients. J Stroke 2019; 21 (01) 105-107
    CrossrefPubMedGoogle Scholar
  • 55 Huang X, MacIsaac R, Thompson JL. et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke 2016; 11 (05) 534-543
    CrossrefPubMedGoogle Scholar
  • 56 Zang Y, Hou J, Wang LY. Therapeutic effect of tenecteplase on treatment of cerebral arterial thrombosis: a meta-analysis. Eur Rev Med Pharmacol Sci 2016; 20 (20) 4369-4379
    PubMedGoogle Scholar
  • 57 Kheiri B, Osman M, Abdalla A. et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis 2018; 46 (04) 440-450
    CrossrefPubMedGoogle Scholar
  • 58 Powers WJ, Rabinstein AA, Ackerson T. et al; American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49 (03) e46-e110
    CrossrefPubMedGoogle Scholar